Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 215

Results For "clinical"

2937 News Found

Tislelizumab plus chemo show promising results for esophageal cancer in Phase III study
Biotech | April 27, 2022

Tislelizumab plus chemo show promising results for esophageal cancer in Phase III study

Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours


Pharming gets positive review from UK MHRA for leniolisib
Biotech | April 26, 2022

Pharming gets positive review from UK MHRA for leniolisib

A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme


Lonza and Integral Molecular partner on biotherapeutics
News | April 26, 2022

Lonza and Integral Molecular partner on biotherapeutics

The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation


SRL Diagnostics opens state-of-the-art laboratory in Jamshedpur
Clinical Trials | April 26, 2022

SRL Diagnostics opens state-of-the-art laboratory in Jamshedpur

The new lab in the industrial town is SRL’s 4th lab in the state of Jharkhand


Sygnature Discovery acquires Peak Proteins
Biotech | April 26, 2022

Sygnature Discovery acquires Peak Proteins

Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes


GSK launches once daily, single inhaler-triple therapy for COPD patients
Drug Approval | April 26, 2022

GSK launches once daily, single inhaler-triple therapy for COPD patients

Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers


DCGI grants Covaxin Emergency Use Approval for children 6-12 years
Drug Approval | April 26, 2022

DCGI grants Covaxin Emergency Use Approval for children 6-12 years

Covaxin was earlier approved for children 12-18 years of age


ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI
Drug Approval | April 26, 2022

ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI

The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age


Shilpa Medicare receives NoC for biosimilar Aflibercept
Biotech | April 25, 2022

Shilpa Medicare receives NoC for biosimilar Aflibercept

Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab


New studies presented at ECCMIC 2022 confirm benefit of remdesivir in treating Covid-19
Biotech | April 25, 2022

New studies presented at ECCMIC 2022 confirm benefit of remdesivir in treating Covid-19

Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment